BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T052214
CREATED:20191215T123515Z
LAST-MODIFIED:20191215T123645Z
UID:23340-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:RAS- Targeted Drug Discovery Summit Europe
DESCRIPTION:After three decades of trial and error to target the driver of 30% of all diagnosed cancers\, scientists are finally making meaningful clinical progression to target the cancer master switch\, the RAS family of proteins. \n \nThe RAS- Targeted Drug Discovery Summit Europe is the only industry-led and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science\, capturing the most pioneering data\, thought-provoking insights and practical lessons learned\, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins\, gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. Hear from the likes of Boehringer Ingelheim\, Sanofi\, Bayer\, Francis Crick Institute\, PhoreMost\, Allinky Biopharma\, Elicio Therapeutics\, Oblique Therapeutics\, Onconova Therapeutics and Revolution Medicines. Visit the website to see the full speaker line-up\, what will be discussed\, pricing and ticket options: https://ter.li/8qb2rr.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-summit-europe/
LOCATION:Hilton Vienna Plaza\, Schottenring 11\, Vienna\, A - 1010\, Austria
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200225
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T052214
CREATED:20200110T081422Z
LAST-MODIFIED:20200110T081422Z
UID:23647-1582588800-1582847999@www.pharmajournalist.com
SUMMARY:8th Neurodegenerative Drug Development Summit
DESCRIPTION:Returning to Boston in February 2020 is the 8th Neurodegenerative Drug Development Summit\, previously World CNS. \nDespite the lack of clinical trial success\, new investments are being made in forward-thinking biotechs\, digital and blood-based biomarker technologies are advancing\, new targets are emerging\, and gene therapy is taking the limelight. \nThe Neurodegenerative Drug Development Summit will unite industry stakeholders to learn how to overcome their translational challenges\, share their progress and network for future collaborations to accelerate the development of successful neurodegenerative therapeutics. \nDon’t miss your opportunity to join over 150 fellow CNS experts from Biogen\, AbbVie\, Sanofi and more\, and immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.
URL:https://www.pharmajournalist.com/event/8th-neurodegenerative-drug-development-summit/
LOCATION:Hyatt Regency Boston\, 1 Avenue de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200226
DTEND;VALUE=DATE:20200228
DTSTAMP:20260515T052214
CREATED:20200217T092303Z
LAST-MODIFIED:20200217T092639Z
UID:24192-1582675200-1582847999@www.pharmajournalist.com
SUMMARY:21st Pharmacovigilance 2020
DESCRIPTION:“Latest developments in pharmacovigilance\, drug safety and RMP” \n21st Pharmacovigilance 2020 event keeps an immersed eye on discussion of critical topics in PV domain\, which capture influence of emerging technologies like AI\, IoT\, Big Data. Not merely that\, we have exciting surprise activities which will help you to interact more with your peers. This will be surely an exciting event wherein you could get chance to meet big industry gems. Let’s gather to shape the industry with your magnificent ideas. \n \nSPONSORS: \n\nCovance\nBrookwood Global\n\nWe also have more sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/Booth/Stall and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. \nDELEGATE REGISTRATION: \nIn order to register please contact us on Email: kavitha@virtueinsight.co.in   \n1 Delegate @ £1299 + VAT \n3 Delegates @ £2598 + VAT \nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/21st-pharmacovigilance-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200303
DTEND;VALUE=DATE:20200305
DTSTAMP:20260515T052214
CREATED:20191215T130603Z
LAST-MODIFIED:20191215T130603Z
UID:23348-1583193600-1583366399@www.pharmajournalist.com
SUMMARY:Animal Microbiome & Nutritional Health Congress
DESCRIPTION:Building on the huge success of our European Animal Microbiome Congress in London this past July\, we are incredibly excited to return to the USA in March 2020\, this time in Chicago\, Illinois. \n \nInterest in animal microbiomes as therapeutics is rapidly expanding\, as techniques to study the microbial world decrease in cost and increase in accessibility\, and case studies from human medicine receive widespread attention. The current state of techniques and strategies to modify the microbiome to improve animal health\, focusing on applications in domestic pets and farm animals\, will be the main focus of this event. \nWe will be untangling the basic biology of microbiome-directed therapies in animals and the examples to date of application of probiotics\, prebiotics\, and other microbiome-directed therapies and feed additives being used to benefit animal health. We will also be looking heavily at the impact of different feed and nutrition profiles on animal microbiomes\, and the power of nutrition in affecting animal health in a beneficial way. \nFinally\, the event will host the Animal Microbiome & Nutritional Health Innovation Showcase\, where 8 emerging companies in the field of animal nutrition will present the microbiome and nutritional solutions they can bring to market. \nTo learn more about this event and to register online\, visit https://animalmicrobiomecongressusa.com/
URL:https://www.pharmajournalist.com/event/animal-microbiome-nutritional-health-congress/
LOCATION:Warwick Allerton – Chicago\, 701 N Michigan Avenue\, Chicago\, IL\, 60611\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200303
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T052214
CREATED:20191215T131423Z
LAST-MODIFIED:20191215T131423Z
UID:23352-1583193600-1583452799@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders
DESCRIPTION:Discover the Clinical & Commercial Potential of Gene Therapy & Editing Approaches Revolutionizing Hemophilia\, Sickle Cell Disease & β-Thalassemia Treatment \nRevolutionary gene therapies are redefining the treatment of blood diseases. \n \nWith an approved gene therapy treatment for β-thalassemia in the EU\, and hemophilia candidates seeking 2020 approval in the USA and beyond\, pioneers in the space must overcome hurdles they have never previously encountered to transform their clinical candidates into a commercial reality. Gene Therapy for Blood Disorders will unite industry leaders across the blood disease space to delve into the specific clinical and commercial challenges faced by companies developing gene therapies for hemophilia\, sickle cell disease and\nβ-thalassemia. \nEvaluate the best strategies for a commercial launch in blood disease\, optimize your trial design\, gain insights on revolutionary novel technologies\, and ultimately enhance your current hematology gene therapy program to bring transformative treatments to patients more quickly and efficiently. \nDownload the full event guide to learn more from companies including bluebird bio\, Spark Therapeutics and Editas Medicine
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders/
LOCATION:Courtyard Boston Downtown\, 275 Tremont Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200304
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T052214
CREATED:20200217T092857Z
LAST-MODIFIED:20200217T093049Z
UID:24197-1583280000-1583452799@www.pharmajournalist.com
SUMMARY:8th Annual Pharma AntiCounterfeiting & Serialisation 2020
DESCRIPTION:8th Annual Pharma AntiCounterfeiting & Serialisation 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI\, IoT and blockchain within pharma and healthcare through a mixture of practical\, lectures and roundtable discussions specifically designed. \nCONFERENCE SPONSORS: \n\nIO AG\n\nWe have sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in \nCONFERENCE DELEGATE PRICING: \nIn order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in \nPlease note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite\, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event. \n \nEarly Bird Discount Price: \n1 Delegate @ £899 + VAT (Valid Till 24th Jan 2020) \n3 Delegates @ £1798 + VAT (Valid Till 25th Jan 2020) \nStandard Price: \n1 Delegate @ £1299 + VAT (Valid from 25th Jan 2020) \n3 Delegates @ £2598 + VAT (Valid from 25th Jan 2020) \nKEY SPEAKERS: \n\nNICHOLAS CALL\, Special Agent\, FDA\nGALIT MEYRAN\, Serialization Global Program Manager\, Teva\nMARCEL DE GRUTTER \, Project Manager Serialization – Regulatory & Government Affairs Liaison\, Abbott\nPATRIK MERCKELL\, External Business Process Analyst and Project Manager\, Roche\nEIKE HILLBRICHT \, Corporate Security Manager\, Boehringer Ingelheim\nJACK JING \, Global Business Development Director / Head of EU Commercial Operations\, Seacross Pharmaceuticals\nLEYLA HANNBECK \, CEO\, Association of Independent Multiple Pharmacies\nSULTAN DAJANI \, Pharmacist Superintendent\, Wainwrights Chemists\nTRACQ ANTOINE\, Head of Commercial Logistics & Serialization\, Galderma\nADRIAN VAN DEN HOVEN\, Director General of Medicines for Europe\, European Medicines Verification Organisation (EMVO)\nMIKE ISLES\, Executive Director\, European Alliance for Access to Safe Medicines\nMONIKA DERECQUE POIS\, Director General\, GIRP—European Healthcare Distribution Association\nBILL ARONSON \, COO\, Artificial Intelligence Research Group\nMARIE MANLEY \, Partner\, Head of the UK Life Sciences Practice\, Sidley Austin\nSANDY EISEN\, Chief Medical Officer\, Fromtline Pharma\n\nPlus many more \nKEY THEMES: \nAnti-counterfeiting\, Serialisation\, T&T \n\nShaping the future for Healthcare\nEffect of Post (FMD) Deadline\nSerialisation strategies- Choosing a Serialisation solution\nAI algorithms to crack down on fake products\nFight the FAKE – Protect the public\nTechnology Impact – Current digital world\nSerialisation and Compliance\nPenetrating the legitimate supply chain\nPackaging Techniques – Protecting your products\n\nBrexit \n\nImpact on EU\, US and Row market\n\nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/8th-annual-pharma-anticounterfeiting-serialisation-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200304
DTEND;VALUE=DATE:20200306
DTSTAMP:20260515T052214
CREATED:20200217T093608Z
LAST-MODIFIED:20200217T093608Z
UID:24207-1583280000-1583452799@www.pharmajournalist.com
SUMMARY:3rd Annual Phrama AI\, IoT & Blockchain 2020
DESCRIPTION:“Competences to Combat Counterfeits & Impact of AI\, IoT\, Blockchain & Big Data in Pharma” \nOur 3rd Annual Pharma AI\, IoT & Blockchain 2020 will provide you insight into the current state of play in the EU & US on the vital role of technology impact in the sustainability of pharma and healthcare systems. Our speakers will outline the key recent developments in technology impact in pharma and healthcare in the EU and other international jurisdictions. The event will also address some of the most achievable possibilities of integrating AI\, IoT and blockchain within pharma and healthcare through a mixture of practical\, lectures and roundtable discussions specifically designed. \nSPONSORS: \n\nio AG\nAdvanco\n\nWe have more sponsorship opportunities available for the event\, which gives you an opportunity to sponsor/speak/exhibit/stall/booth and create brand awareness. In addition\, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts. For further details please contact Kavitha at Email: kavitha@virtueinsight.co.in \n \nCONFERENCE DELEGATE PRICING: \nPlease note that this is a PAID event and NOT A FREE event (no complimentary passes available). Any invite\, email or tickets issued mentioning it as a free pass or free ticket to this event through any third party site will strictly not be accepted by the organizer and entry won’t be granted at the event. \nIn order to Register as delegate for the conference please contact Kavitha at kavitha@virtueinsight.co.in \n1 Delegate @ £1299 + VAT \n3 Delegates @ £2598 + VAT \nKEY SPEAKERS: \n\nSTEVEN ABRAHAMSON\, Senior Director\, Product Cyber Security\, GE Healthcare\nPATRIC JARCHOW \, Head of Global Multi-Channel Strategy\, Merck KGaA\nNICLAS NILSSON \, Head of Open Innovation in Research\, LEO Pharma\nSTEVEN WILLIAMSON\, Audit Account Director\, Information Security\, GSK\nEDDIE GUZDAR \, Medical Head UK & Ireland | Physician | Venture Capital & Board Advisor – Digital Technology\, Sanofi Genzyme\nNATALIA M.MONTEIRO\, Clinical Trial Budget & Metrics Management\, Takeda Pharmaceuticals\nPINGPING NI\, Director\, Biometrics Team Lead\, AstraZeneca\nALAN HOW\, Strategy & Operations – Global Commercial\, Merck\nHUSSAIN AL MUSCATI \, Customer Engineering Lead\, Life Sciences\, Google\nMARCO GUIDOBALDI \, Sales Engineer – Healthcare & Life Sciences\, Google\nEBERHARD SCHEUER \, Chairman\, HIT Foundation\nGABOR PURMAN \, Senior Account Director\, Patient Services and Medical Education\, NexGen Healthcare Communications\nROMIKA BHOWMICK\, Senior Manager – Digital Commercial (Europe & International Markets)\, Teva\nBRAM VAN LEEUWEN \, Lead (digital) Innovation BeNeLux\, Sanofi\nEVI MATHIOU\, Legal\, Compliance & Quality Manager BA Europe East & South\, Novo Nordisk\nMYLES FURNACE\, Digital Health and Data Lead\, UK & Ireland Speciality Care\, IPSEN\nRAMESH KRISHNAMURTHY \, Strengthen international institutions\, WHO (World Health Organization)\nSIDDHI TRIVEDI \, Healthcare Innovator\, Co-founder\, Beyond Identity \nALF GOEBEL\, CEO\, Advanco\nIGNACIO H. MEDRANO\, Founder & Chief Medical Officer\, SAVANA\nEDITH LECOMTE NORRANT \, CEO & CSO\, IPSOMEDIC\nROBIN SMITH\, Security and Information Assurance Lead\, Independent Office for Police Conduct (IOPC)\n\nPlus many more \nKEY THEMES: \nAI and IoT \n\nApplications in Pharma and Healthcare\nChallenges and opportunities\nUse of AI in drug discovery\nRole of Cyber Security in age of IoT and Healthcare Hacks\nIP – Cybercrime in the pharmaceutical industry: a booming business\nTransforming the healthcare and pharmaceutical industry\n\nBlockchain \n\nHow it transforms pharma and healthcare\nBlockchain in Logistics and Supply Chain\nA must learn technology\nBlockchain technology and start-ups – where do you get started?\nApplication areas for blockchain within healthcare?\n\nBig Data \n\nPotential future in synchronicity of data\nBig data =Big impact\nA Revolution in Drug Discovery and Pharma R&D\nHow to involve patients better to develop drugs\n\nBrexit \n\nImpact on EU\, US and Row market\n\nGet more from the event\, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time\, meet the leading companies showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.
URL:https://www.pharmajournalist.com/event/3rd-annual-phrama-ai-iot-blockchain-2020/
LOCATION:Pestana Chelsea Bridge Hotel\, London\, United Kingdom
ORGANIZER;CN="Virtue Insight":MAILTO:kavitha@virtueinsight.co.in
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200310
DTEND;VALUE=DATE:20200313
DTSTAMP:20260515T052214
CREATED:20191218T094051Z
LAST-MODIFIED:20191218T094051Z
UID:23467-1583798400-1584057599@www.pharmajournalist.com
SUMMARY:Inborn Errors of Metabolism Drug Development
DESCRIPTION:Join over 80 inherited metabolic disease drug developers and KOLs to explore how the key challenges prohibiting accelerated drug development are being addressed. The inaugural Inborn Errors of Metabolism Drug Development Summit will provide a discursive platform to examine where pioneering gene therapy modalities intersect with current therapeutic options and explore how diseases can be better targeted in order to address the huge unmet medical need for rare metabolic diseases. \nWith scarce treatment options leaving inborn errors of metabolism a devastating\, unfilled and unmet medical need\, the opportunity for biopharma to do better and aggressively tap into a lucrative and life changing market of gene modalities is growing. For the first time\, the Inborn Errors of Metabolism Drug Development summit will look to examine how the experience within existing pharmacology for rare metabolic diseases can be leveraged with the drug development strategies of those pioneering gene modalities to improve efficacy\, safety and commercial viability. \nIncorporating insights from industry-leading speakers\, this conference will delve into the key patient access\, regulatory\, clinical and commercial hurdles that need to be overcome in order to address the unmet medical need of rare metabolic diseases and fulfil their full commercial potential. \nThis is your comprehensive guide to define your drug development path for 2020. Don’t miss out on your chance to network with industry leaders and be a part of the only enriched industry forum focused on accelerating the development of better effective treatments for inborn errors of metabolism. \nTo know more about Inborn Errors of Metabolism Drug Development please click here.
URL:https://www.pharmajournalist.com/event/inborn-errors-of-metabolism-drug-development/
LOCATION:Courtyard Boston Downtown/North Station\, 107 Beverly Street\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200312
DTEND;VALUE=DATE:20200314
DTSTAMP:20260515T052214
CREATED:20191031T101142Z
LAST-MODIFIED:20191031T104348Z
UID:23118-1583971200-1584143999@www.pharmajournalist.com
SUMMARY:4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
DESCRIPTION:In the past decade\, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies\, cancer vaccines\, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction. \n \nOur 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London\, UK would address the challenges and future directions in IO research. The congress aims to bring academicians\, researchers and scientists from research institutes pharmaceutical\, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s\, Bispecific Antibodies\, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies\, pre-clinical and translational immune-oncology developments\, updates in cellular and viral therapies\, vaccines development and personalized immunotherapy. Keynote presentations\, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. \nKey Sessions: \n\nUpdates in development of monoclonal antibodies\, ADC’s and Bispecific Ab’s\nImmune Checkpoint Inhibitors and Combinations\nPreclinical and Translational Immuno-Oncology Developments (Preclinical models for Immunecheckpoint modulators)\nBiomarkers and Cancer Vaccines\nCAR-T cell therapy\, T Cell Therapy\nTumor microenvironment\nOncolytic Viruses\nMicrobiome in Cancer Immunotherapy\n\nTo learn more about 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress click here \n 
URL:https://www.pharmajournalist.com/event/4th-annual-marketsandmarkets-next-gen-immuno-oncology-congress/
LOCATION:ILEC Conference Center and IBIS London Earls Court\, 47 Lillie Road\, London\, SW6 1UD
ORGANIZER;CN="MarketsandMarkets Research Private Ltd.":MAILTO:shardul.oza@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200316
DTEND;VALUE=DATE:20200318
DTSTAMP:20260515T052214
CREATED:20191101T085034Z
LAST-MODIFIED:20191101T085034Z
UID:23143-1584316800-1584489599@www.pharmajournalist.com
SUMMARY:AI in Drug Discovery Conference 2020
DESCRIPTION:Leveraging machine learning – discovery to the next level! \nSMi group presents the launch of the inaugural AI in Drug Discovery conference taking place in London on 16th-17th March 2020. \nAI-empowered machine learning technologies hold the potential of reducing drug discovery associated costs by US$ 70 billion in the upcoming 10 years. With an estimated +39% CAGR\, AI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nThe presence of AI in drug discovery is tangible with the majority of drug discovery scientist already working with AI-enabled platforms using machine learning and deep learning\, neural networks and natural language processing. However\, there is a long journey ahead of optimizing AI-human connections and understanding the full potential of AI-enabled tools and platforms. \n \nBENEFITS OF ATTENDING: \n\nListen to case studies form industry leader pharmaceutical and biotechnology that have already incorporated AI into their work\nExplore how Deep Learning Methods can be leveraged for compound screening\, de novo design\, multiparameter optimization/ ADME toxicity property predictions\, chemical synthesis route predictions\nDiscover strategies for overcoming data-related challenges such as lack of consistent and quality data at the heart of AI and strategies for improving data access\nDefine unique discovery approaches such as fragment-based drug discovery and network-driven drug discovery\n\nJoin us at SMi’s inaugural AI in Drug Discovery 2020 Conference and explore the latest AI-enabled approaches for lead compound screening\, multi parameter optimization\, disease modelling\, drug synthesis and design. \nTo register please visit: www.AI-indrugdiscovery.com/pharmajwl \nPLUS\, one interactive half-day post-conference workshop \nPractical application of predictive properties in drug design\, Workshop Leader: Robert Young\, Blue Burgundy Ltd. \nEarly-Bird Rates \n\nBOOK BY 29TH NOVEMBER AND SAVE £400\nBOOK BY 13TH DECEMBER AND SAVE £200\nBOOK BY 31ST JANUARY AND SAVE £100\n\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiDrugdiscovery\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/ai-in-drug-discovery-conference-2020/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200317
DTEND;VALUE=DATE:20200319
DTSTAMP:20260515T052214
CREATED:20191215T125706Z
LAST-MODIFIED:20191215T125706Z
UID:23344-1584403200-1584575999@www.pharmajournalist.com
SUMMARY:Formulation & Delivery Series US
DESCRIPTION:Join over 250 leaders\, experts and researchers at the Formulation & Drug Delivery US Series\, connecting global pharma\, biotech and academia for high-level discussions on the latest innovations for biopharmaceutical development. \n \nThe Formulation & Drug Delivery Congress will discuss the state of the industry\, looking at new strategies for optimizing biologic formulations such as antibodies\, proteins and vaccines\, as well as highlighting key updates in amorphous solid dispersions and combination products. \nAlongside this\, The Inhalation & Respiratory Drug Delivery Congress will examine the latest developments in inhaled vaccines and antibiotics\, alongside challenges and trends in generic formulation. \nFeaturing over 55+ renowned industry speakers from leading organisations such as Merck\, Takeda and AstraZeneca\, this programme will allow you to discuss the key topics that interest you. \nView the Programme: https://bit.ly/33nCbI2 \n 2020 Live Webinars: \n‘The Design And Development Of A Connected Inhalation System To Help With Monitoring And Patient Adherence’ – Hosted by Paul Upham\, Head\, Smart Devices\, Genentech  \n“Understanding Supersaturation Of Small Molecule To Improve Oral Bioavailability”  – Hosted by Sudhakar Garad\, Global Head of Chemical and Pharmaceutical Profiling\, Novartis Institutes for BioMedical Research \n“Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development” – Hosted by Hovik Gukasyan\, Associate Director\, Early Development Formulation and Physical Chemistry\, Allergan \nWebinar Registration:  https://bit.ly/2qvy91O \nGo Social: For the latest conference updates follow us on Twitter @FDDCongress and join the congress conversation on #FDDUS20  \nFor more information about the event\, please contact Guillaume Alonso at g.alonso@oxfordglobal.co.uk
URL:https://www.pharmajournalist.com/event/formulation-delivery-series-us/
LOCATION:Hilton San Diego Mission Valley\, 901 Camino del Rio South\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Oxford Global":MAILTO:g.alonso@oxfordglobal.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200403
DTSTAMP:20260515T052214
CREATED:20191104T104106Z
LAST-MODIFIED:20191104T121228Z
UID:23228-1585526400-1585871999@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Rare Disorders
DESCRIPTION:The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. \nWith approvals in a number of indications over the last year\, and more rapidly approaching on the horizon\, the meeting will leverage the experience from first to market pioneers\, as well as unveiling the strategies\ndrug developers are employing to improve efficacy\, safety and commercial viability. \nIncorporating insights from 80+ industry-leading speakers\, this conference will delve into the key regulatory\, reimbursement\, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies. \nJoin 600+ of your colleagues to accelerate the progress of the next generation of gene therapies. \nThis is your comprehensive guide to define your commercial path forward in 2020. \nTo know more about 4th Annual Gene Therapy for Rare Disorders click here.
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-rare-disorders/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200402
DTSTAMP:20260515T052214
CREATED:20191215T132020Z
LAST-MODIFIED:20191215T132020Z
UID:23357-1585526400-1585785599@www.pharmajournalist.com
SUMMARY:Cell Engager Summit
DESCRIPTION:The Cell Engager Summit is the only meeting focused on developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \n \nUnderstand the very latest in construct design\, immune cell biology\, tumor associated activation\, toxicity assessment\, solid tumor targeting strategies\, clinical insights and more. \nDiscover how to effectively scale complicated manufacturing of multi-specific cell engagers to reduce production costs and time whilst ensuring purity and quality of antibodies. \nWith 22+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders\, this conference will focus solely on cell engaging drugs and how to tackle key clinical and commercial challenges. \nTo learn more about this event and to register online\, visit https://ter.li/hkw9b8
URL:https://www.pharmajournalist.com/event/cell-engager-summit-2020/
LOCATION:Courtyard Boston Downtown\, 275 Tremont Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200330
DTEND;VALUE=DATE:20200401
DTSTAMP:20260515T052214
CREATED:20191215T210012Z
LAST-MODIFIED:20200323T125422Z
UID:23453-1585526400-1585699199@www.pharmajournalist.com
SUMMARY:SMi’s 22nd Annual Superbugs & Superdrugs Conference
DESCRIPTION:A Focus on Non-traditional Approaches in the Fight against Antimicrobial Resistance \nSponsored by Scynexis \nCO-CHAIRS FOR 2020: Cara Cassino\, Chief Medical Officer\, Contrafect and Michael Dawson\, Director\, Mike Dawson Antimicrobial Research Consultancy \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.superbugssuperdrugs.com \nAs one of the most impactful pharmaceuticals for maintaining public health\, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal\, including colistin\, carbapenems\, 3rd and 4th generation cephalosporins\, useless. \n \nThis year’s event aims to showcase a suite of sessions focused on novel drugs and approaches\, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR. \nIt is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR\, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR\, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020\, along with leaders from the pharmaceutical industry\, academia\, regulatory and funding bodies\, and public-private partnerships to discuss the way forward. #SMiBugs \nFEATURED SPEAKERS FOR 2020: \n\nYuri Gleba\, Professor\, Founder\, Nomad Bioscience\nMark Albrecht\, Branch Chief\, Antibacterials program\, BARDA/HHS\nPaul Finn\, CEO\, Oxford Drug Design\nCara Cassino\, Chief Medical Officer\, Contrafect\nMartin Everett\, CSO\, Antabio\nSamareh Lajaunias\, Director\, Combioxin SA\nFrancois Moreau\, Scientific Director\, Mutabilis\nEmma Leire\, Microbiology Lead\, Centauri Therapeutics\nLorenzo Corsini\, Co-Founder/CEO/R&D\, Phagomed\nStephen Barat\, VP\, Preclinical Research and Early Development\, Scynexis\nColm Leonard\, Consultant Clinical Adviser/Consultant Thoracic Physician/Honorary Pro \n\nWHATS ON THE AGENDA FOR 2020? \n\nDiscuss the new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins from Nomad Bioscience\nGain valuable insight towards fighting severe and resistant infections through neutralising bacterial virulence effectors from Combioxin\nExamine a UK project looking at novel value assessment and reimbursement for novel antimicrobials from NICE/Manchester University NHS Foundation Trust\nExplore direct lytic agents (DLAs) and their potential as a successful disruptive anti-infective technology with Contrafect\nEvaluate the utility of machine learning and AI in antibiotic drug discovery with Oxford Drug Design\n\nTo register visit www.superbugssuperdrugs.com/PJWL \nEARLY BIRD-RATES \n\nREGISTER BY 29TH NOVEMBER AND SAVE £400http://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/Holiday Inn Kensington ForumHoliday Inn Kensington Forum\nREGISTER BY 13TH DECEMBER AND SAVE £200\nREGISTER BY 31ST JANUARY AND SAVE £100
URL:https://www.pharmajournalist.com/event/smis-22nd-annual-superbugs-superdrugs-conference/
LOCATION:Holiday Inn Kensington Forum\, 97 Cromwell Rd Kensington\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group Limited":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200401
DTEND;VALUE=DATE:20200403
DTSTAMP:20260515T052214
CREATED:20190906T095018Z
LAST-MODIFIED:20190906T095018Z
UID:22300-1585699200-1585871999@www.pharmajournalist.com
SUMMARY:3rd Annual Pharma Supply-Chain & Security World 2020
DESCRIPTION:The Annual Pharma Supply Chain and Security World Summit is back in London for the 3rd time\, and this time with more focus on optimizing your supply chain challenges to ensure an agile\, responsive\, streamlined and secured supply chain. Pharmaceutical companies have to resist the challenges looming from supply chain security lapses to avoid infiltration of counterfeit\, diverted\, and adulterated drugs entering into the supply chain. \nTo protect your brand and build a genuine future\, Corvus Global Events invites you to Pharma Supply Chain & Security World 2020 – Supply-chain\, Drug Serialization And Anti-Counterfeiting conference\, which will have Pharma industry experts sharing various challenges faced\, new strategies\, case studies and use of innovative ideas\, the conference will also offer opportunities to encourage partnerships and collaborations. In this conference you’ll not only discover innovative technologies\, transformation strategies and collaboration methods\, but how best to implement them to optimise your supply chain processes and strategies for drug anti-counterfeiting. \nTo learn more and to register online\, visit: http://bit.ly/2lB3X2E
URL:https://www.pharmajournalist.com/event/3rd-annual-pharma-supply-chain-security-world-2020/
ORGANIZER;CN="Corvus Global Events":MAILTO:info@corvusglobalevents.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200407
DTEND;VALUE=DATE:20200410
DTSTAMP:20260515T052214
CREATED:20200204T131833Z
LAST-MODIFIED:20200204T131833Z
UID:24006-1586217600-1586476799@www.pharmajournalist.com
SUMMARY:4th Advanced Sourcing R&D Procurement in Pharma Summit
DESCRIPTION:Join the 4th Advanced Sourcing R&D Procurement in Pharma Summit to: Discover How Can R&D Procurement Enhance SRM\, Expedite Speed-to-Market & Deliver Beyond TCO.  As the only meeting catered to the needs of senior R&D Procurement\, Sourcing and Category Management leaders\, we have seen the transformation since we launched this meeting in 2017. Over the last 3 years\, we have witnessed the industry begin to mature – procurement leaders play an increasingly important role as strategic business partner and innovation enabler\, supporting R&D to progress into clinic and commercialization. \nBe part of this growing community where you can share your common challenges and be inspired by fellow colleagues from pharma and biotech.  Find out more > https://ter.li/8mwudk
URL:https://www.pharmajournalist.com/event/4th-advanced-sourcing-rd-procurement-in-pharma-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200408
DTEND;VALUE=DATE:20200409
DTSTAMP:20260515T052214
CREATED:20200318T114724Z
LAST-MODIFIED:20200318T124952Z
UID:24662-1586304000-1586390399@www.pharmajournalist.com
SUMMARY:Temperature Controlled Logistics in Biopharmaceuticals US
DESCRIPTION:Temperature Controlled Logistics in Biopharmaceuticals US 2020 is going virtual! \nNow in its 4th year\, Temperature Controlled Logistics is going VIRTUAL to deliver key\, actionable insights into very latest regulatory requirements\, technological innovations\, strategic developments\, and how to implement them into your commercial and clinical logistics with both maximum efficiency and minimal cost. \nTemperature Controlled Logistics will bring you everything you need to ensure a successful and compliant implementation for storage and distribution. With a more interactive and hands on agenda including panel discussions; roundtables; speed networking; think tanks; mini workshops and more\, this event will create an environment where storage and distribution teams from across all sizes of manufacturer can work together to manage creative\, technical\, and regulatory demands while ensuring patients are safeguarded at all stages. \nJoin pharmaceutical\, medical device and biotechs experts to discuss new trends and opportunities and learn how to optimize temperature maintenance with the supply chain.
URL:https://www.pharmajournalist.com/event/temperature-controlled-logistics-in-biopharmaceuticals-us/
LOCATION:Virtual Event
ORGANIZER;CN="Arena International":MAILTO:kadin.luong@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200414
DTEND;VALUE=DATE:20200418
DTSTAMP:20260515T052214
CREATED:20191105T115338Z
LAST-MODIFIED:20200407T153017Z
UID:23236-1586822400-1587167999@www.pharmajournalist.com
SUMMARY:eyeforpharma Philadelphia Virtual
DESCRIPTION:“As we self-isolate\, we must be careful not to isolate our ideas and thoughts. Ironically\, it has never been more important for our industry to share\, collaborate and inspire. For that reason\, we have not cancelled the eyeforpharma Philadelphia meeting\, but we’re moving it online. It is also now entirely free of charge to attend. I’m humbled that the speakers and supporters that were due to present are moving online with us\, and share with us a desire to ‘do what we can’ to make sure that we carry on communicating. I believe the event will be stronger than ever\, and more influential – at just the right time.” \n \nPaul Simms\, Chairman\, eyeforpharma \nWhy eyeforpharma Philadelphia Virtual is essential viewing: \n\nIt’s free for all to join: In such a difficult time\, we want to unify the industry and we’ve taken the decision to allow anyone to sign up to listen live\, ask questions and participate. If you work for a pharma or biotech\, you’ll also get access to a full meeting service so you can set up bespoke 1-1 meetings with fellow attendees.\n\n\nA speaker faculty even better than before: You’ll learn from 100+ speakers with 60+ free sessions – presentations\, panels\, fireside chats\, interactive workshops and Q&A\, You’ll also see hours of additional live and on-demand content\, including never-before-seen interviews with Kabir Nath\, President & CEO North America\, Otsuka\, Julie Gerberding\, EVP and Chief Patient Officer\, Communications\, Global Policy and Population Health\, Merck\, James Musick\, VP and Head of Digital Transformation\, Neurology\, UCB\, and many more.\n\n\nConnect with industry leaders around the world: Without the constraints of geography\, we’ll have thousands of industry leaders from across the globe coming together to network and collaborate.\n\n\nComplete virtual meetings platform: Send messages to connect 1-on-1 with your fellow attendees. Schedule meetings and use a virtual private meeting room to chat.\n\n\nFull virtual exhibition: Showcasing over 50+ exhibitors\, search for the latest services and technology solutions from your desk\, watch demo videos and the ability to share your virtual business card.\n\nRegister for FREE here: https://bit.ly/2UPFCVZ Join the conversation and become healthcare’s solution.
URL:https://www.pharmajournalist.com/event/eyeforpharma-philadelphia-virtual/
LOCATION:Online\, PA
ORGANIZER;CN="eyeforpharma":MAILTO:ksharp@eyeforpharma.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200415
DTEND;VALUE=DATE:20200418
DTSTAMP:20260515T052214
CREATED:20191215T132554Z
LAST-MODIFIED:20191215T132652Z
UID:23361-1586908800-1587167999@www.pharmajournalist.com
SUMMARY:Neuroimmunology Drug Development Summit 2020
DESCRIPTION:More and more pharma and biotech companies are investing in research focused on neuroimmunology and neuroinflammation’s relation to neurodegenerative diseases in the challenge to develop clinically effective therapeutics. \n \nThe 2nd Neuroimmunology Drug Development Summit’s agenda has specifically designed alongside neuroimmunology experts from the likes of Denali\, AbbVie and Biogen to help these drug developers to overcome their translational challenges and successfully translate their drug candidates into the clinic. \nImmerse yourself in the field’s cutting-edge scientific advances and take this unrivaled opportunity to join over 23 expert industry speakers and over 80 drug developers from the neuroimmunological community for over 7 hours of dedicated networking time and 2 deep-dive workshops. \nTo find out more and view the full speaker line-up\, download the full event guide.
URL:https://www.pharmajournalist.com/event/neuroimmunology-drug-development-summit-2020/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200420
DTEND;VALUE=DATE:20200423
DTSTAMP:20260515T052214
CREATED:20200309T093538Z
LAST-MODIFIED:20200309T093538Z
UID:24547-1587340800-1587599999@www.pharmajournalist.com
SUMMARY:2nd Digital Health  for Pharma (DH4P)
DESCRIPTION:Digital Health for Pharma (DH4P) is the leading Digital Health conference specifically developed for pharmaceutical and life science commercial organizations. Co-created by Evolution Road and ExL Events’ Digital Pharma Series teams\, the three-day event serves to educate life science organizations on how best to leverage digital tools to enhance the commercial model of health and pharma; while also educating patients and bridging the gap between knowledge and information\, pre-commercial and commercialization. \n \nFor 2020\, ExL Events and strategic partners at Evolution Road explore five core leverage models of learning: \n\nINVEST\nINCUBATE/ACCELERATE\nCOMMERCIALIZE\nCOLLABORATE\nCO-DEVELOP\n\nLearn more: http://bit.ly/2TJ2cOh
URL:https://www.pharmajournalist.com/event/2nd-digital-health-for-pharma-dh4p/
LOCATION:Philadelphia\, PA\, Philadelphia\, PA\, United States
ORGANIZER;CN="ExL Events%2C a division of Questex%2C LLC":MAILTO:awarren@questex.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200422
DTEND;VALUE=DATE:20200425
DTSTAMP:20260515T052214
CREATED:20200309T092247Z
LAST-MODIFIED:20200309T092247Z
UID:24541-1587513600-1587772799@www.pharmajournalist.com
SUMMARY:9th Digital Marketing for Medical Devices West
DESCRIPTION:Digital Marketing for Medical Devices is the premier event in the west coast for medical device companies to explore best practices and innovations to improve their digital marketing strategy. Med device companies will hear from their peers in the industry as well as marketing agencies who will reveal the most effective methods to market their products in a digital age. \n \nThe event takes place in San Francisco\, one of the largest tech hubs in the world\, as the medical device industry in this region is expanding at a rapid pace. DMMD West provides a platform to assist this rapid expansion. From innovation through research and development\, marketing and data analytics\, communication and branding strategies\, and measuring KPIs and ROIs\, this event serves to assist your organization\, small and large\, along your product life cycle. \nLearn more: http://bit.ly/39xKlke
URL:https://www.pharmajournalist.com/event/9th-digital-marketing-for-medical-devices-west/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
ORGANIZER;CN="ExL Events%2C a division of Questex%2C LLC":MAILTO:awarren@questex.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200428
DTEND;VALUE=DATE:20200501
DTSTAMP:20260515T052214
CREATED:20200218T083428Z
LAST-MODIFIED:20200218T083428Z
UID:24226-1588032000-1588291199@www.pharmajournalist.com
SUMMARY:Manufacturing Assets & Facility Management in Pharma
DESCRIPTION:Pharma\, biotechs and CMOs have witnessed a major transformation with the continued adoption of digital manufacturing and emerging technologies using AI and big data. We have seen pioneers\, including the likes of Sanofi and Merck\, to maximize asset value\, increase plant reliability and ensure production continuity through digitization. \nThe inaugural Manufacturing Assets & Facility Management (MAFM) in Pharma Summit has been specifically designed to help you manage cost pressures and boost productivity through digitization where you will advance various aspects of asset and facility management programs such as clarity of asset inventory\, asset lifecycle\, facility footprint and sustainability. \n \nWhy is this Event for You? Join this cutting-edge discussion to: \n\nGet up to speed with the digital transformation to streamline operations\nFind new approaches to strategic asset management to improve inventory visibility\nUse data to enhance asset utilization and track the full lifecycle of assets\nEmploy energy and sustainability initiatives to reduce utilities spend\nManage MRO processes to improve productivity and reduce costs\n\nImmerse yourself in this industry-led meeting with the likes of Merck\, CSL Behring and Seattle Genetics. This event is dedicated to exploring strategies in the manufacturing environment where you will join 60+ senior experts from functions of Manufacturing Engineering\, Manufacturing Operations\, Facility Management\, Asset Management\, Procurement and Maintenance & Reliability across pharma\, biotech and CMOs. \nRegister with your team today and don’t miss out on this unique meeting to engage with peers and re-define best practice for tomorrow’s operations.
URL:https://www.pharmajournalist.com/event/manufacturing-assets-facility-management-in-pharma/
LOCATION:Wyndham Boston Beacon Hill 5 Blossom Street Boston\, MA\, MA 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200429
DTEND;VALUE=DATE:20200430
DTSTAMP:20260515T052214
CREATED:20200407T145113Z
LAST-MODIFIED:20200407T145318Z
UID:24936-1588118400-1588204799@www.pharmajournalist.com
SUMMARY:Recombinant Chromogenic Assay as Alternate Methods for the Bacterial Endotoxins Test (BET)
DESCRIPTION:Recombinant Chromogenic Assay as Alternate Methods for the Bacterial Endotoxins Test (BET)\nConference: 29 April 2020 – 10am EDT (3pm BST – UK time)\nLocation: WEBINAR\nWebsite: https://www.smi-online.co.uk/pharmaceuticals/webinar/recombinant-chromogenic-assays \nHOSTED BY: Associate of Cape Cod\nLED BY: Veronika Wills\, Manager\, Technical Services\, Associates of Cape Cod \n \nRecently\, there has been a lot of interest associated with the potential use of synthetic (non-animal based) reagents for bacterial endotoxin testing. This webinar will provide an in-depth overview of the global perspective on the use of such reagents\, including their regulatory status. \nThis free to join webinar is sponsored by Associate of Cape Cod\, the one hour webinar will focus on executing a recombinant kinetic chromogenic assay\, testing samples and detailed data interpretation with the primary focus on comparability of the data with conventional amoebocyte lysate- based assays. \nBENEFITS FOR JOINING THE WEBINAR: \nThis interactive webinar will provide the following benefits: \n\nAn overview of global status of recombinant reagents for BET\nA session on kinetic chromogenic testing\nData interpretation\nTroubleshooting kinetic chromogenic assays\nEquivalency of the recombinant reagents to LAL reagents\n\nWHO SHOULD JOIN? \n\nSenior Microbiologists\nLead Scientists\nLaboratory Managers\nQA Specialists\nDrug Substance External Manufacturers\nQC Scientists\nHeads of Quality\nBusiness Development Managers\nPharmaceutical Microbiology Consultants\nHigher Pharmacopoeia Scientists\nAnalytical Standards Specialists\n\nFor full details and to register your free place\, please visit: https://www.smi-online.co.uk/pharmaceuticals/webinar/recombinant-chromogenic-assays
URL:https://www.pharmajournalist.com/event/recombinant-chromogenic-assay-as-alternate-methods-for-the-bacterial-endotoxins-test-bet/
LOCATION:WEBINAR
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200504
DTEND;VALUE=DATE:20200508
DTSTAMP:20260515T052214
CREATED:20191215T133346Z
LAST-MODIFIED:20191215T133426Z
UID:23365-1588550400-1588895999@www.pharmajournalist.com
SUMMARY:NASH Summit Boston
DESCRIPTION:The NASH Summit offers a wide range of cutting-edge debates across 4 conference tracks: discovery\, translational\, non-invasive biomarker and clinical drug development\, in addition to a selection of workshops and seminars. This convivial discussion and networking forum has an extensive program set to help you approach your pipeline for the upcoming year. \n \nJoin 80+ speakers\, including our conference Chair Jason Campagna\, Senior Vice President & Global NASH Lead at Intercept\, and 350+ attendees as the community comes together again by addressing their challenges and the consequences of change in the NASH market. \n\nEstablish a plan of action to optimize candidate success by evaluating advances and difficulties and learn from the community’s experience\nTranslate anti-fibrotic efficacy into the clinic by learning about ground-breaking preclinical modalities\nUse the latest practical insights into hepatocyte differentiation to improve your target identification by understanding its impact on immune cells\, ductular reaction and fibrosis\nExamine the payer’s thoughts on the need to biopsy and assess the clinical utility of non-invasive diagnostics in the normal algorithm of care\nConnect NASH reduction in phase 2 and NASH resolution in phase 3 while justifying a systemic approach to address NASH in combination\, as a manifestation of wider metabolic dysfunction\n\nDownload the full event guide or get in touch today for the agenda and speaker line-up!
URL:https://www.pharmajournalist.com/event/nash-summit-boston/
LOCATION:50 Park Plaza at Arlington Street\, Boston\, MA\, 02116-3912\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200511
DTEND;VALUE=DATE:20200513
DTSTAMP:20260515T052214
CREATED:20180202T092329Z
LAST-MODIFIED:20200319T094546Z
UID:9152-1589155200-1589327999@www.pharmajournalist.com
SUMMARY:SMi’s 20th Annual Pain Therapeutics Conference
DESCRIPTION:SMi’s 20th Annual Pain Therapeutics Conference\nDiscover Cutting Edge Research and Novel Therapeutics in the Pipeline \nConference: 11 and 12 May 2020\nLocation: REMOTE ACCESS ONLY\nWebsite: http://www.pain-therapeutics.co.uk/PharmaJournWL \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.pain-therapeutics.co.uk \nThe price to be a part of this conference is £999 (remote access) and registration is available via the conference website at www.pain-therapeutics.co.uk \nThe 20th Annual Conference will overview the current state of pain treatment starting with research essentials including choosing the right preclinical models to overviewing clinical success up to date\, highlighting cutting-edge research and evaluating the potential of drug candidates in the pipelines of leading pharmaceuticals. \n \nThis year we are introducing the Pain Research Essentials theme to closely observe analgesics drug development from a preclinical point of view. Within this theme talks will address the latest biomarker discoveries\, bridging the translational gap\, differences of pain pathology across sexes and consequently\, the need for distinct gender animal models. This will be topped with a panel discussion around novel drug targets in neuropathic pain treatment.  \nPresentations on clinical stage research will highlight current struggles of opioid-based treatments and discuss results of treatments with non-opioid targets; such as the recently researched cannabinoid receptor 2\, nociception/orphanin FQ peptide (NOP) receptor\, ENKephalinase and NGF receptors. Furthermore\, neuro-immune interactions and their role in pain pathology will be discussed as an anticipated approach for providing more effective therapy for chronic pain. Additionally\, the therapeutic efficacy of neurotoxins will be addressed exploring novel botulinum-based constructs.  \nJoin SMi’s leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires. \nEvent Hashtag: #SMiPain \nView the full agenda: http://www.pain-therapeutics.co.uk/PharmaJournWL \nWHO SHOULD ATTEND \nChief Executive Officer\, Chief Scientific Officers\, Chief Medical Officers\, Managing Directors\, CEO\, Head of Department\, Principal Research Scientists\, Clinical lead\, Clinical Operations in the following fields: \n\nPain and Migraine\nInflammation\nChronic Pain\nNeuropathic Pain\nAnalgesic pre-clinical development\nAnaesthesia and Pain Management\nCNS clinical trials\nIon Channel Pharmacology\nPharmacology Intelligence\nTranslational science\nDrug development\nExploratory development\n\nEARLY BIRD-RATES \n\nBOOK BY 28TH FEBRUARY AND SAVE £200\nBOOK BY 31ST MARCH AND SAVE £100
URL:https://www.pharmajournalist.com/event/smi-pain-therapeutics-conference/
LOCATION:REMOTE ACCESS ONLY
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200511
DTEND;VALUE=DATE:20200513
DTSTAMP:20260515T052214
CREATED:20180307T074833Z
LAST-MODIFIED:20200323T125717Z
UID:11545-1589155200-1589327999@www.pharmajournalist.com
SUMMARY:Highly Potent Active Pharmaceutical Ingredients (HPAPI)
DESCRIPTION:SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020. \nAnnouncement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only – please register your place at www.highlypotentapi.com \nThe price to be a part of this conference is £999 (remote access) and registration is available via the conference website www.highlypotentapi.com \n \nHPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology\, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits\, assessing hazards\, implementing risk procures\, translating risk assessment into facility engineering\, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines. \nAttend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry. \nNetwork and learn from leading professionals such as: \nCHAIR FOR 2020 – Justin Mason-Home\, Director\, HPAPI Project Services Limited \nKEY SPEAKERS INCLUDE: \nPascal Michoux\, Vice President\, Global EHS Teva api & Biologics\, teva API Italy\nWilliam Hawkins\, Manager Occupation Toxicology\, GsK\nBrian Edwards\, Chair\, Pharmaceutical Human Factors Group\, CIeHf\nThomas Adam\, Head of GQA Chemical APIs\, Bayer AG\nIldikó Ziegler\, QA Manager\, Gedeon Richter\nFrancois D’Hooge\, ADC Project Manager\, Gamamabs Pharma\nAndreas Schreiner\, Head of Validation\, Novartis \nFEATURED HIGHLIGHTS: \n\nExplore HPAPI manufacturing with 8 big pharma from both the toxic substance and the employees’ perspective\nGain better understanding of human factors and ergonomics aspects and their role in improving production performance with the Chartered Institute of Ergonomics and Human Factors\nDeep dive into the oncology market and ADC production\, the main driver of the HPAPI industry\nLearn what it takes to create a safety company culture and how to better train your employees on risk perception\n\nView the full agenda: www.highlypotentapi.com \nContact Info: \nT: +44 (0) 20 7827 6164\nE: nhoward@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/highly-potent-active-pharmaceutical-ingredients-hpapi/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd.":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200513
DTEND;VALUE=DATE:20200515
DTSTAMP:20260515T052214
CREATED:20190912T073738Z
LAST-MODIFIED:20190912T073738Z
UID:22362-1589328000-1589500799@www.pharmajournalist.com
SUMMARY:4th Annual Global Clinical Trials Connect 2020 - Collaboration\, Innovation and Enhancing Quality in Clinical Trials
DESCRIPTION:The 4th Annual Global Clinical Trials Connect 2020 will provide a platform to discuss on the futuristic advancements in clinical trials and clinical research. This multidisciplinary program involves broad participation of people from clinical trials community from around the globe who are focused on learning more about clinical research\, clinical trials planning and management. \nKey Highlights \n\nPatient Recruitment and Site selection\nInnovative trial designs\nPartnership & Collaboration – Sponsors\, CROs\, Sites and External Vendors\nPatient centric clinical trials\nNew innovations in Patient Recruitment planning and execution on a clinical trial\nOutsourcing strategies and models\nElectronic Clinical Outcome Assessment and Electronic Patient Reported Outcome\nStreamlined IRT development process\nPharmacovigilance & Clinical Trials\nPost-Clinical Trial closed communities\nHow to future proof your clinical operations\nImplementing Risk Based Monitoring\nStreamlining R&D and lower costs in clinical trials\nAdaptive Trial Model\nClinical Trial Auditing\nReal World Clinical Trial Strategies\nData Quality & Technology\nClinical Data Strategy & Analytics\nClinical Technology and Driving Innovation\nM-Health\, Wearable and Consumer Technology\nBig-Data\, IoT and Artificial Intelligence Technology in Clinical trials\nBlockchain technology for improving clinical research quality
URL:https://www.pharmajournalist.com/event/4th-annual-global-clinical-trials-connect-2020-collaboration-innovation-and-enhancing-quality-in-clinical-trials/
LOCATION:Holiday Inn London – Kensington High St. Wrights Ln\, Kensington\, London W8 5SP\, UK
ORGANIZER;CN="Corvus Global Events":MAILTO:info@corvusglobalevents.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200519
DTEND;VALUE=DATE:20200521
DTSTAMP:20260515T052214
CREATED:20200318T114228Z
LAST-MODIFIED:20200318T114228Z
UID:24652-1589846400-1590019199@www.pharmajournalist.com
SUMMARY:Outsourcing in Clinical Trials East Coast
DESCRIPTION:Discover effective strategies for outsourcing clinical trial operations to ensure studies run smoothly and within budget \n\nArena International are delighted to announce Outsourcing in Clinical Trials East Coast will be returning to King of Prussia in May for its 11th Annual event!\n\nThe 2020 programme will feature a range of speakers from the likes of GlaxoSmithKline\, Novartis\, Pfizer\, BMS any many more\, who through a variety of interactive session formats will offer insight on promoting successful collaboration between the clinical trials community. Attendees will have the opportunity of taking part in sessions across 3 stages\, each focusing on a different topic area. Whether your role is Clinical Operations\, Technology & Innovation or Clinical Data Management this event can not be missed\n\nWe look forward to seeing you there!
URL:https://www.pharmajournalist.com/event/outsourcing-in-clinical-trials-east-coast/
LOCATION:Valley Forge Casino Resort – 1160 1st Ave\, King of Prussia\, PA 19406\, United States
ORGANIZER;CN="Arena International":MAILTO:kadin.luong@arena-international.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200525
DTEND;VALUE=DATE:20200531
DTSTAMP:20260515T052214
CREATED:20200511T104035Z
LAST-MODIFIED:20200511T104403Z
UID:25449-1590364800-1590883199@www.pharmajournalist.com
SUMMARY:Digital Health Online Summit
DESCRIPTION:The healthcare industry will never be the same after COVID19. \nHealthcare professionals need to stay aware of the latest digital health activities and keep learning from leading organizations. \n \nDigital Health Online Summit is a 6-day virtual summit\, providing a comprehensive overview of the current digital health activities\, and equipping health professionals with strategies and tactics\, examples and guidelines for a successful healthcare transformation. \nThis online summit will provide you with timely insights into the following areas: \n\nDigital Health – Current Activities in different organizations\nSmart Care\, Patient Centricity and Engagement\nTransformation with VR/AR\, Voice Tech\, IoT\, Wearables\nBig Data\, AI and Machine Learning\nThe digital mindset transformation\nPatient staff engagement and culture change\nNew Horizon\, Innovation and Tomorrow’s Perspectives\n\nWithin each topic\, there will be 5-9 speaking sessions\, using case studies and bringing practical examples. The summit will gather 40 expert speakers from great companies and associations from all around the world\, including Europe\, North America and Australia. \nWhile the standard events require a lot of time\, effort\, logistics\, and significant expenses for travel and accommodation\, Digital Health Online Summit takes advantage of today’s technologies and provides the best content for professionals from all around the world. \nTo mention just some of the speaker’s companies: United Health Group\, HNS\, Dignity Health\, European Health Management Association\, WONCA\, Stanford Virtual Human Interaction Lab\, XpertCare Inc.\, Seton Health Alliance\, Deloitte\, KPMG\, Mednax\, Crossroads Hospice & Palliative Care\, CitiusTech\, Partners HealthCare\, Peninsula Regional Health System\, Philips\, Ramsay Santé and others. \nThis is a great possibility to learn directly from C-Suite executives with unique and timely insights about the digital shift towards better health services. \nHere are just some of the case studies and presentations: \n➤ Visions and Strategies for Virtual care services\n➤ Current Challenges of Digitalization in the Healthcare Industry\n➤ Key components of a successful digital transformation strategy\n➤ How to keep the conversation open with HCPs while they are not available (COVID-19 crisis time)\n➤ Frontline digital healthcare strategy – from business as usual to crisis management\n➤ Digital when possible – physical when needed\n➤ Personalized\, digitally-supported\, out- of-hospital care: A patient case study\n➤Digital Therapeutics: Just Like a pill?\n➤ Innovation in times of a global crisis \nAnd much\, much more. \nFor our members and network\, we have FREE REGISTRATIONS to this great online summit. \nGet your FREE PASS here >> https://www.digitalhealthonlinesummit.com/?utm_source=partner \nHope you can join the event!
URL:https://www.pharmajournalist.com/event/digital-health-online-summit/
LOCATION:Online
ORGANIZER;CN="Digital Health Online Summit":MAILTO:ilya@digitalhealthonlinesummit.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200603
DTEND;VALUE=DATE:20200605
DTSTAMP:20260515T052214
CREATED:20200203T102138Z
LAST-MODIFIED:20200204T132652Z
UID:23987-1591142400-1591315199@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Human
DESCRIPTION:Previously known as North American Microbiome Congress\, Microbiome Connect: Human USA is all about connecting leading academics and biotech companies presenting preclinical and clinical data\, to network\, educate and share knowledge. Join key opinion leaders and 50+ expert speakers across three dedicated tracks of content to examine the latest preclinical and clinical data in extra-intestinal and intestinal indications. \nTo know more about Microbiome Connect: Human please click here.
URL:https://www.pharmajournalist.com/event/microbiome-connect-human/
LOCATION:Boston\, MA\, MA\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR